SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy
Aurélie Truffot, Julien Andréani, Marion Le Maréchal, Alban Caporossi, Olivier Épaulard, Raphaële Germi, Pascal Poignard, Sylvie Larrat
Abstract
A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleotide polymorphisms and whole-genome sequencing. Rapid emergence of spike receptor binding domain mutations was found, associated with a compartmentalization of viral populations.
Topics & Concepts
VirologyBiologyAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Single-nucleotide polymorphismGenomeCoronavirus disease 2019 (COVID-19)ImmunologyMedicineGenotypeGeneGeneticsInfectious disease (medical specialty)DiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchBacteriophages and microbial interactions